Pharsight

Drugs that contain Sacubitril; Valsartan

1. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
ENTRESTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796331 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(1 year, 1 month ago)

US8404744 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2023

(1 year, 1 month ago)

US8404744

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(7 months ago)

US8796331

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2023

(7 months ago)

US7468390 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Nov, 2023

(2 months ago)

US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
May, 2024

(3 months from now)

US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jan, 2025

(10 months from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(1 year, 4 months from now)

US9388134 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(2 years from now)

US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(3 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2027

(3 years from now)

US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Aug, 2033

(9 years from now)

US11058667 NOVARTIS PHARMS CORP Sacubitril-valsartan dosage regimen for treating heart failure
May, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Feb 16, 2024

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb...

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents